A detailed history of Algert Global LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Algert Global LLC holds 224,216 shares of VERV stock, worth $1.26 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
224,216
Previous 137,496 63.07%
Holding current value
$1.26 Million
Previous $671,000 61.7%
% of portfolio
0.03%
Previous 0.02%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$4.4 - $7.86 $381,568 - $681,619
86,720 Added 63.07%
224,216 $1.09 Million
Q2 2024

Aug 14, 2024

BUY
$4.76 - $12.79 $654,480 - $1.76 Million
137,496 New
137,496 $671,000
Q4 2023

Feb 14, 2024

SELL
$8.84 - $18.7 $66,918 - $141,559
-7,570 Reduced 42.0%
10,452 $146,000
Q2 2023

Aug 14, 2023

BUY
$13.34 - $19.9 $98,582 - $147,061
7,390 Added 69.51%
18,022 $338,000
Q1 2023

May 12, 2023

SELL
$14.3 - $24.01 $79,193 - $132,967
-5,538 Reduced 34.25%
10,632 $153,000
Q4 2022

Feb 13, 2023

BUY
$17.85 - $40.7 $288,634 - $658,119
16,170 New
16,170 $313,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $336M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Algert Global LLC Portfolio

Follow Algert Global LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.